Data from circulating tumor DNA (ctDNA) testing were generated for over 1,900 samples across at least 3 time points in a phase 3 clinical trial and used to build a machine learning model to predict patient survival. The model accurately identified patients with a high risk of disease recurrence and could provide a basis for assigning therapies in phase 1/2 clinical trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fojo, A. T. & Noonan, A. Why RECIST works and why it should stay – counterpoint. Cancer Res. 72, 5151–5157 (2012). An overview of the history of Response Evaluation Criteria in Solid Tumors (RECIST).
Petrelli, F. et al. Surrogate endpoints in immunotherapy trials for solid tumors. Ann. Transl. Med. 7, 154 (2019). An overview article of imaging-based surrogate endpoints in immunotherapy trials for solid tumors.
Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer. 17, 223–238 (2017). A review article that discusses potential applications of circulating tumor DNA in oncology.
Socinski, M. A. et al. IMpower150 final overall survival analyses for atezolizumab plus bevacicumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J. Thorac. Oncol. 16, 1909–1924 (2021). An article that provides background on the IMpower150 study used for the model development in our research.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Assaf, Z. J. F. et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat. Med. https://doi.org/10.1038/s41591-023-02226-6 (2023).
Rights and permissions
About this article
Cite this article
High-resolution circulating tumor DNA testing predicts survival in metastatic lung cancer clinical trials. Nat Med 29, 797–798 (2023). https://doi.org/10.1038/s41591-023-02258-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02258-y
